Reverse gene therapy

Details Reverse gene therapy Reverse gene therapy

2005-02-08

2005-02-08

Li, Janice (Department: 1632)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S069100, C435S320100, C435S325000, C435S455000, C424S093200, C424S093600, C536S023500

Reexamination Certificate

active

06852704

ABSTRACT:
The invention relates to compositions and methods for reverse gene therapy, wherein a gene therapy vector encoding a gene product (e.g. a protein) which is usually only expressed in cells of an abnormal tissue is delivered to a cell of an animal afflicted with a disease or disorder to alleviate the disease or disorder. In one embodiment, a plasmid vector encoding HERG (A561V) protein is delivered to a cell of an animal afflicted with re-entrant atrial flutter-mediated cardiac arrhythmia.

REFERENCES:
patent: 4160452 (1979-07-01), Theeuwes
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 5034506 (1991-07-01), Summerton et al.
patent: 6207383 (2001-03-01), Keating et al.
Alton et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial pp. 947-654 vol 353, 1999.*
Boucher et al. J Clin Invest 1999 Feb.; 103:441-5.*
Okuyama T et al. Gene Ther 1998 Aug.; 8:1047-53.*
Vinyals et al. Gene Ther 1999 Jan.; 6:22-33.*
Bradley et al, J Clin Invest 1999 Mar.; 102;889-96.*
Mazhari, Cir Res 2002:90:842-3.*
Anderson et al., 1995, J. Biomed. Mater. Res. 29:1473-1475.
Anderson et al., 1995, Tissue Eng. 1:323-326.
Antman, 1996, Am. J. Cardiol. 78:67-72.
Arenal et al., 1999, Circulation 99:2771-2778.
Bello et al., 1985, J. Biomol. Struct. Dyn. 2:899-913.
Biben et al., 1996, Develop. Biol. 173:200-212.
Brauner et al., 1997, J. Thorac Cardiovasc Surg 114:923-933.
Buchanan et al., 1993, J. Cardiovasc. Pharmacol. 33:10-14.
Chen et al., 1995, Human Gene Therapy 6:917-926.
Chiquet et al., 1996, Biochem. Cell Biol. 74:737-744.
Chubet et al., 1996, Biotechniques 20:136-141.
Cochrane et al., 1996, Drug Ther. Bull. 34:41-45.
Copertino et al., 1997, Proc. Natl. Acad. Sci. USA 94:1846-1851.
Cosio et al., 1996, Pacing Clin. Electrophysiol. 19:965-975.
Cosio et al., 1993, Lancet 341:1189-1193.
Cosio et al., 1996, Arch. Mal. Coeur Vaiss. 1:75-81.
Couffinhal et al., 1997, Hum. Gene Ther. 8: 929-934.
Cox et al., 1993, Ann. Thorac. Surg. 56:814-823.
Cox et al., 1995, J. Thorac. Cardiovasc. Surg. 110:485-495.
Desai et al., 1996, Pharm. Res. 13:1838-1845.
Desai et al., 1997, Pharm. Res. 14:1568-1573.
Fei et al., 1997, Circ. Res. 80:242-252.
Field, Science 239:1029-1033.
Frame, 1996, Cardiol. Clin. 14:471-481.
Franz et al., 1997, Cardiovascular Research 35:560-566.
Froissart et al., 1998, Clin. Gen. 53:362-368.
Gibson et al., 1995, In:Molecular Interventions and Local Drug Delivery in Cardiovascular Disease, Edelman, Ed., W.B. Saunders Co., Ltd., London, UK, pp. 327-352.
Gottsauner-Wolf et al., 1997, Am. Heart J. 133:329-334.
Guzman et al., 1996, Circulation 94:1441-1448.
Hammond et al., 1997, Analyt. Chem. 69:1192-1196.
Huang et al., 1995, Nature 378:292-295.
Humphrey et al., 1997, Adv. Drug Delivery Rev. 24: 87-108.
Hunter et al., 1995, J. Biol. Chem. 270:173-178.
Jain et al., 1991, Anal. Biochem. 199:119-124.
Kaab et al., 1998, Circulation 98:1383-1393.
Kaplan et al., 1998, Biochem. Pharmacol. 55:373-382.
Kim et al., 1998, J. Clin. Invest. 101:1821-1826.
King et al., 1997, J. Biol. Chem. 272:28518-28522.
Labhasetwar et al., 1994, J. Cardiovasc. Pharm. 24:826-840.
Labhasetwar et al., 1995, Clin. Pharmacokinet. 29:1-5.
Labhasetwar et al., 1995, Proc. Natl. Acad. Sci. USA 92:2612-2616.
Labhasetwar et al., 1997, Adv. Drug Del. Rev. 24:109-120.
Labhasetwar et al., 1997, Adv. Drug. Del. Rev. 24:63-85.
Labhasetwar et al., 1998, J. Cardiovasc. Pharmacol. 31:449-455.
Lasic (1997, In:Gene Delivery, Lipsows, Ed., CRC Press, Boca Raton, Florida, pp. 33-37 and 56-61.
Levy et al., 1995, J. Controlled Release 36:137-147.
Levy et al., 1996, Drug Delivery 3:137-142.
Martin et al., 1995, Nature 375:691-694.
Martinez-Fong et al., 1994, Hepatology 20:1602-1608.
Mason et al., 1998, Gene Therapy 5:1098-1104.
McDonald et al., 1997, Nature 388:289-292.
Milano et al., 1994, Proc. Natl. Acad. Sci. USA 91: 10109-10113.
Miyamoto et al., 1998, J. Cell. Physiol. 177:58-67.
Nakao et al., 1998, Am. J. Pathol. 152:1237-1245.
Natale et al., 1996, Am. J. Cardiol. 78:1431-1433.
Nielsen et al., 1991, Science 254: 1497.
Nishina et al., 1997, Nature 385:350-353.
Priori et al., 1997, PACE 29:2052-2057.
Radler et al., 1997, Science 275:810-814.
Ranger et al., 1998, Nature 392:186-190.
Rauch et al., 1998, Am. J. Med. Gen. 78:322-331.
Robbins, 1997, Trends Cardiovasc. Med. 7:185-191.
Robbins and Ghivizzani, 1998, Pharmacol. Ther. 80:35-47.
Roden et al., 1996, Annu. Rev. Med. 47:135-48.
Rodefeld et al., 1996, J. Thorac. Cardiovasc. Surg. 112:898-907.
Sanguinetti et al., 1995, Cell 81:299-307.
Sanguinetti et al., 1996, Nature 384:80-83.
Sanguinetti et al., 1996, Proc. Natl. Acad. Sci. USA. 93:2208-2212.
Schneider et al., 1998, FEBS Letters 429:269-273.
Schwendeman et al., 1995, Pharm. Res. 12:790-795.
Shelness et al., 1994, J. Biol. Chem. 269:9310-9318.
Sintov et al., 1997, Int. J. Pharm. 146:55-62.
Solway et al., 1995, J. Biol. Chem. 270:13460-13469.
Song et al., 1997, J. Controlled Release 45:177-192.
Subramanian et al., 1995, Cell Growth Differ. 6: 131-137.
Villa et al., 1995, Circ. Res. 76:505-513.
Waldo, 1994, Clin. Cardiol. 17:1121-1126, 1994.
Wang et al., 1997, Current Op. Cardio. 12:310-320.
Wells et al., 1979, Circulation 60:665-673.
Wolfert et al., 1996, Gene Therapy 3:269-273.
Wolfert et al., 1996, Human Gene Therapy 7:2123-33.
Wood et al., 1995, In:Molecular Interventions and Local Drug Delivery in Cardiovascular Disease, Edelman, Ed., W.B. Saunders Co., LTD, London, UK, pp. 399-471.
Zhou et al., 1999, J. of Biol. Chem. 274:31123-31126.

Affiliated with

Also associated with

Rating

Reverse gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Reverse gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reverse gene therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3459452